
2. Alloway R. Generic Tacrolimus: Good Medicine or Cheap Fix?? Results of U01 study comparing tacrolimus brand and the 2 most disparate generics in renal and liver transplant recipients, University of Cincinnati Liver Transplant Patient Support Group, Cincinnati, OH, August, 2016.


17. Fang L. Establishing the Bioequivalence (BE) for Pediatric Formulations: OGD Perspective, Challenges and Strategies to Facilitate Formulation Development of Pediatric Drug Products; a symposium sponsored by the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), College Park, MD, June 8, 2016.


23. Jiang W. FDA town hall update on generic AEDs, American Epilepsy Society (AES), Houston, TX, December 5, 2016.


28. Kanfer I. The Development And Application Of Surrogate Methods To Assess Bioequivalence Of Topical Generic Products Intended For Local Action,3rd Bioequivalence Summit: Ensure Regulatory Compliance When Demonstrating the Bioequivalence of New Dosage Forms, Delivery Methods and Biosimilars, Boston, MA, September 26, 2016.


42. Murthy SN. Beyond Q1/Q2—Comparing the Arrangement of Matter (Q3) and Performance, The American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Denver, CO, November 12, 2016.


50. Polli JE. Non-Inferiority Assessment for Iron-Carbohydrate Complexes, 2016 Research Day - University of Maryland School of Pharmacy, Baltimore, MD, April 22, 2016.


52. Raney SG. Dosage Form And Function: Bioavailability And Bioequivalence Implications For Topical Dermatological Products, AAPS 2016, Denver, CO, November 12, 2016.


60. Sinner F. Dermal Open Flow Microperfusion (DoFM) for the Bioequivalence Assessment of Topical Products Based on Skin PK, International Conference and Expo on Generic Drug Market and Contract Manufacturing, Barcelona, Spain, November 07, 2016.

62. Stinchcomb AL. Bioavailability And Bioequivalence Of Products Applied To The Skin, Third Bioequivalence Summit: Ensure Regulatory Compliance When Demonstrating the Bioequivalence of New Dosage Forms, Delivery Methods and Biosimilars, Boston, MA, September 26, 2016.


77. Zhao L. Scientific And Regulatory Background For The Revised Bioequivalence Requirements For NTI, Steep Exposure-Response, And Drugs With Complex PK Profiles, 2016 AAPS Annual Meeting, Denver, CO, November 15, 2016.